

1 **Clonal spread of *Plasmodium falciparum* candidate artemisinin partial resistance *Kelch13* 622I**  
2 **mutation and co-occurrence with *pfhrp2/3* deletions in Ethiopia**

3 Abebe A. Fola <sup>1,2\*</sup>, Sindew M. Feleke <sup>3\*</sup>, Hussein Mohammed <sup>3</sup>, Bokretsion G. Brhane <sup>3</sup>, Christopher M.  
4 Hennelly <sup>4</sup>, Ashenafi Assefa <sup>3,4</sup>, Rebecca M. Crudal <sup>1,2</sup>, Emily Reichert <sup>5</sup>, Jonathan J. Juliano <sup>4</sup>, Jane  
5 Cunningham <sup>6</sup>, Hassen Mamo <sup>7</sup>, Hiwot Solomon <sup>8</sup>, Geremew Tasew <sup>3</sup>, Beyene Petros <sup>7</sup>, Jonathan B Parr  
6 <sup>4\*</sup> Jeffrey A. Bailey <sup>1,2\*</sup>

7 (\* co-first and senior authors)

8

9 **Affiliations**

10 <sup>1</sup>Center for Computational Molecular Biology, Brown University, Providence, RI, USA

11 <sup>2</sup>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University,  
12 Providence, RI, USA

13 <sup>3</sup>Ethiopian Public Health Institute, Addis Ababa, Ethiopia

14 <sup>4</sup>Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA

15 <sup>5</sup>Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA, USA

16 <sup>6</sup>Global Malaria Programme, World Health Organization, Geneva, Switzerland

17 <sup>7</sup>Department of Microbial, Cellular and Molecular Biology, College of Natural and Computational Sciences,  
18 Addis Ababa University, Addis Ababa, Ethiopia

19 <sup>8</sup>Federal Ministry of Health, Addis Ababa, Ethiopia

20

21 **Corresponding:**

22 Jeffrey A. Bailey, MD, PhD

23 Mencoff Family Associate Professor of Translational Research, Associate Professor of Pathology and  
24 Laboratory Medicine

25 Box G-E5, Providence, RI 02912, USA

26 Tel: 401-444-5160

27 Fax: 401-444-4377

28 Email: [jeffrey\\_bailey@brown.edu](mailto:jeffrey_bailey@brown.edu)

29

30 **Key words:** *Kelch13*, 622I, *Pfhrp2/3*-deletion, Ethiopia, Malaria

31

32 **Abstract**

33 The emergence and spread of drug- and diagnostic-resistant *Plasmodium falciparum* are major  
34 impediments to malaria control and elimination. We deep sequenced known drug resistance mutations and  
35 other informative loci across the genome of 609 samples collected during a study across three regions of  
36 Ethiopia. We found that 8.0% (95% CI 7.0-9.0) of malaria cases were caused by *P. falciparum* carrying  
37 the candidate artemisinin partial-resistance *K13 622I* mutation, which occurred less commonly in  
38 diagnostic-resistant *pfhrp2/3*-deleted than normal non-deleted parasites ( $p=0.03$ ). Identity-by-descent  
39 analysis showed that 622I parasites were significantly more related than wild-type ( $p<0.001$ ), consistent  
40 with recent expansion and spread. *Pfhrp2/3*-deleted parasites were also highly related, with evidence of  
41 clonal transmissions at the district level. Parasites carrying both *pfhrp2/3* deletion and 622I mutation were  
42 observed in some sites. These findings raise concern for future spread of combined drug- and diagnostic-  
43 resistant parasites and warrant close monitoring.

44

45

46

47

48

49

50

51

52

53

54

55

56

57

## 58 Introduction

59 Despite intensified malaria control efforts, progress toward elimination has stalled in recent years. Malaria  
60 cases increased across many endemic countries in Africa, where 96% of malaria deaths occur primarily  
61 due to *Plasmodium falciparum*<sup>1</sup>. The World Health Organization (WHO) recommends artemisinin-  
62 combination therapies (ACTs), such as artemether-lumefantrine (AL) or artesunate-amodiaquine (AS-  
63 AQ), as the first-line treatments for uncomplicated *P. falciparum* malaria<sup>2</sup>. However, the parasite has  
64 evolved drug resistance to most available antimalarial drugs<sup>3,4</sup> and history demonstrates that resistant  
65 strains can rapidly spread<sup>5,6</sup>. Since 2008, *P. falciparum* parasites resistant to first-line ACTs have emerged  
66 in Southeast Asia<sup>7,8</sup> and have spread to neighboring regions<sup>9,10</sup>.

67 Increasing reports across Africa indicate reduced efficacy of artemisinins, with slowed clearance times and  
68 increased recrudescences<sup>11-14</sup>. Mutations in *kelch13* (*K13*) associated with partial resistance to artemisinins  
69 have now also been reported in Uganda, Tanzania and Rwanda<sup>15-17</sup>. In addition, parasites undetectable by  
70 widely used *P. falciparum* rapid diagnostic tests (RDTs), owing to deletion mutations of the histidine-rich  
71 proteins 2 and 3 (*pfhrp2/3*) genes, have emerged in the Horn of Africa<sup>18-20</sup>. Together, these mutations  
72 threaten both components of existing test-and-treat programs, as co-occurrence of *pfhrp2/3* deletions and  
73 *K13* mutations would yield parasites resistant to both diagnosis and treatment. Improved understanding of  
74 how these mutations emerge, interact, and spread is critical to the success of future malaria control and  
75 elimination efforts across Africa.

76 In Ethiopia, malaria is endemic across 75% of the country, with 65% of the population at risk<sup>21</sup>. Over five  
77 million episodes of malaria occur each year, but transmission is highly heterogeneous and seasonal<sup>22</sup>.  
78 Prompt diagnosis and treatment with efficacious drugs is a cornerstone of the malaria program<sup>23</sup>. ACTs  
79 are first-line treatment for uncomplicated falciparum malaria since 2004 throughout the country. However,  
80 chloroquine (CQ) is still widely used and efficacious for cases of endemic vivax malaria<sup>24</sup>. Artemether-  
81 lumefantrine remains highly efficacious<sup>25</sup>, though detection of the candidate artemisinin resistance *K13*  
82 622I mutation in northern Ethiopia<sup>26,27</sup> and high prevalence of residual submicroscopic parasitemia  
83 following ACT treatment in recent studies raises concern<sup>12,25</sup>.

84 Countries such as Ethiopia provide important opportunities to investigate the impact of drug and diagnostic  
85 resistance mutations and how they may co-evolve and spread. To our knowledge, there are no published  
86 studies addressing the prevalence of drug resistance mutations among *pfhrp2/3*-deleted versus non-deleted

87 strains, nor their transmission patterns. We sought to bridge this knowledge gap by conducting a  
88 comparative genomic analysis of drug resistance among *pfhrp2/3*-deleted and non-deleted parasites  
89 collected across three regions of Ethiopia. Using molecular inversion probe (MIP) sequencing for highly-  
90 multiplexed targeted genotyping<sup>28,29</sup>, we determine the prevalence of key drug resistance mutations and  
91 detect spatial patterns of related 622I mutant and *pfhrp2/3*-deleted *P. falciparum* strains. We demonstrate  
92 a high prevalence of the 622I mutation across three regions and co-occurrence with *pfhrp2/3* deletion in  
93 Ethiopia as well as clonal transmission of *pfhrp2/3* deleted parasites at district level.

94

## 95 **Results**

### 96 **MIP sequence data filtering and complexity of infections estimation**

97 A total of 920 samples previously genotyped and MIP sequenced for *pfhrp2/3* deletions from three regions  
98 of Ethiopia (Amhara = 598, Gambella = 83, Tigray = 239) (**Supplementary Figure S1**) were included in  
99 this analysis, representing dried blood spots taken from a subset of the overall series of 2637 malaria cases  
100 (Amhara = 1336, Gambella = 622, Tigray = 679) (**Table S1**). Samples had been collected from rural areas  
101 in 12 districts as part of a large *pfhrp2/3* deletion survey of those 12,572 study participants (56% male,  
102 44% female, age ranges 0 and 99 years) presenting with clinical signs and symptoms of malaria<sup>18</sup>. For this  
103 study, all samples were further MIP captured and sequenced using both i) a drug resistance panel  
104 comprising 814 probes designed to target mutations and genes associated with antimalarial resistance and  
105 ii) a genome-wide SNP panel comprising 1832 probes designed for assessment of parasite relatedness and  
106 connectivity (**Supplementary Data 1 and 2**). Parasite densities across samples ranged from 3 to 138,447  
107 parasites/ $\mu$ l with median parasitaemia of 1,411 parasites/ $\mu$ l (**Supplementary Figure S2A**); as expected,  
108 MIP sequencing coverage was parasite density-dependent (**Supplementary Figure S2B**). All resistance  
109 genotypes with sufficient depth and quality were included in downstream analysis. After filtering for  
110 sample missingness and removing loci with low coverage (**Supplementary Figure S3**), 609 samples and  
111 1395 SNPs from the genome-wide panel (**Supplementary Figure S4, Supplementary Data 3 and 4**)  
112 were included in downstream relatedness analysis.

113 Using filtered genome-wide SNPs, we calculated complexity of infection (COI) and adjusted for the  
114 relative proportion of DBS sampled from participants with discordant vs. concordant RDT results since  
115 the parent *pfhrp2/3* survey purposefully oversampled the former. We estimate that the majority (82.4%)

116 of cases are monogenomic infections (COI = 1) (**Supplementary Figure S5, Table S1**), reflecting  
117 relatively low ongoing transmission in the study areas. Overall, COI per sample ranged from 1 to 4 with  
118 variability at the district level (**Supplementary Figure S5C**), consistent with heterogeneous malaria  
119 transmission at local scale.

### 120 ***K13* 622I mutation is prevalent in Ethiopia across all regions sampled**

121 Analysis of the drug-resistance markers revealed a high prevalence (8.0%, [95% confidence interval (CI)  
122 7.0-9.0]) of samples expected to carry the WHO candidate artemisinin partial resistance mutation 622I  
123 within the propeller domain of *K13*. The 622I mutation had only been previously described in Africa at a  
124 single site in Amhara near the Sudan border in 2014 at 2.4% prevalence<sup>26</sup>. Our results confirmed parasites  
125 with 622I in all 3 regions surveyed as well as all 12 districts (**Figure 1A**). Highest prevalence was observed  
126 in Amhara (9.8%, [95% CI 8.2-11.4]) in the northwest near the Sudan border, followed by Tigray (8.4%,  
127 [95% CI 6.2-10.5]) near the Eritrea border, and Gambella (3.6%, [95% CI 2.1-4.8]) bordering South Sudan,  
128 however, there was high spatial heterogeneity at the district level and within regions (**Table S1**). An  
129 additional 8 non-synonymous mutations were identified across the *K13* gene at low frequencies (<3%)  
130 except for K189T (44.4%), which is frequently observed in Africa and not associated with resistance  
131 (**Figure 1B**). None of the other mutations were WHO-validated or candidate artemisinin partial resistance  
132 mutations, and only two (*K13* E401Q and E433D) fell within the propeller region (**Figure 1B, bottom**  
133 **panel, Supplementary Table S1**). To gain insight into relative fitness of 622I, we compared within-  
134 sample allele proportions in mixed mutant and wild-type infections (n =16). On average, wild-type  
135 parasites occurred at relatively higher proportions (mean = 0.59) compared with 622I mutant parasites  
136 (mean = 0.41) (Mann-Whitney  $p = 0.025$ ) in participants infected by more than one strain, suggesting  
137 lower fitness of mutant strains. The power of this analysis was limited as polygenomic infections were rare  
138 in this study but is consistent with competitive blood stage fitness costs.

### 139 ***K13* 622I mutant parasites carry background mutations that may augment ACT resistance**

140 In addition to *K13* mutations, we found a number of key mutations in other *P. falciparum* genes associated  
141 with resistance to different antimalarial drugs (**Figure 1C, Table S2**), including ACT partner drugs.  
142 Mutations in the *P. falciparum* multidrug resistance gene 1 (*pfmdr1*), particularly isolates that carry the  
143 NFD haplotype (N86Y (wild), Y184F (mutant), and D1246Y (wild)) have been associated with decreased  
144 sensitivity to lumefantrine<sup>30</sup>. Overall, 83% of samples carry the NFD haplotype (**Figure 2**), and 98%

145 (60/61) of 622I mutant parasites carry *pfmdr1* NFD haplotypes. Although this difference was not  
146 significant (Fisher's exact  $p = 0.34$ ), the presence of 622I mutant parasites with *pfmdr1* NFD haplotypes  
147 raises questions about how the genetic background of 622I influences ACT efficacy in Ethiopia. We also  
148 investigated other mutations previously identified as backbone loci on which artemisinin partial resistance  
149 associated *K13* mutations are most likely to arise or could augment ACT resistance<sup>31</sup>. No parasites sampled  
150 in this study carried such background mutations (*pfdd*-D193Y, *pfcert*-I356T, *pfarps*-V127M and *pfmdr2*-  
151 T484I), with the exception of *pfcert*-N326S, which 98% of *K13* 622I and 81% of wild-type parasites carried  
152 (Fisher's exact  $p < 0.001$ ) (**Figure 2**). The co-occurrences of 622I with the *pfmdr1* NFD haplotype and  
153 *pfcert*-N326S raise concern about the efficacy of both artemisinin and partner drugs like lumefantrine in  
154 Ethiopia. We also observed drug-resistance mutations in other genes (**Table S3**), with high prevalence and  
155 some spatial heterogeneity in the distribution of mutations associated with sulfadoxine-pyrimethamine  
156 (SP) resistance (**Supplementary Figure S6**).

### 157 **Co-occurrence of drug-resistance mutations and *pfhrp2/3* deletions**

158 Overall, the *K13* 622I mutation is more common among *pfhrp2/3* non-deleted parasites (26/223, 11.6%)  
159 than *pfhrp2/3* double-deleted parasites (5/110, 4.5%), though not significantly (Fisher's exact  $p = 0.07$ ).  
160 However, higher mean prevalence of 622I mutation is observed among *pfhrp2/3* non-deleted parasites at  
161 the district level (T-test  $p = 0.03$ ) (**Figure 3A**), which could be consistent with deleterious effects from the  
162 combination and/or independent origins with slow intermixing. We repeated this analysis using  
163 permutation by randomly reassigning double- and non-deleted groups and took the mean difference of  
164 these new groups. The permutation analysis shows -8.7% mean difference (F-statistic  $p = 0.02$ ) in  
165 prevalence of 622I among *pfhrp2/3*-deleted vs. non-deleted parasites, suggesting patients infected by  
166 double-deleted parasites are more likely misdiagnosed and less likely receive ACTs according to the  
167 country test and treat policy that result in less ACT drug pressure. We observed a negative correlation  
168 between these mutations at the level of the individual collection sites, suggesting different sites generally  
169 harbor one mutation or the other at high frequency. However, we observed a small number ( $n = 5$ ) of  
170 parasites with both 622I mutation and *pfhrp2/3* deletion in sites where mutation or deletion frequency is  
171 high (**Figure 3B**), confirming that recombination between parasites with these mutations is possible.  
172 Interestingly, 622I is more common among *pfhrp3*-deleted parasites (29/169, 17.2%) compared to  
173 wildtype *pfhrp2/3* non-deleted (26/223, 11.2%) but the difference was not statistically significant (Chi-  
174 square  $p = 0.23$ ).



175 We also examined co-occurrence of *pfhrp2/3* deletions and other drug resistance mutations, particularly  
176 *pfcr*t mutations as most *pfhrp2/3* deletion reports to-date have emerged in areas where *P. vivax* and *P.*  
177 *falciparum* are sympatric and chloroquine is used to treat vivax malaria<sup>32</sup>. We observed overall high  
178 prevalence (median 84% across districts) of *pfcr*t mutations (codon 74-76) (**Supplementary Figure S7A**).  
179 The prevalence of *pfcr*t-K76T mutation was greater among *pfhrp2/3*-deleted (96.3%) compared to non-  
180 deleted (73.8%) parasites, but the difference was not statistically significant (Chi-square  $p = 0.15$ ,  
181 **Supplementary Figure S7B**). This finding suggests patients infected by *pfhrp2/3*-deleted parasites may  
182 be more often exposed to chloroquine.

### 183 **Population structure of *K13 622I* and *pfhrp2/3*-deleted *P. falciparum* in Ethiopia**

184 We investigated genetic population structure using principal component analysis (PCA), which revealed  
185 clustering of parasites by *K13 622I* mutation (PC1) and by *pfhrp2/3* deletion (PC2) status, but not by  
186 geography (**Figure 4, Supplementary Figure S8A**). Overall, 13.4% of variation in our dataset was  
187 explained by these first two principal components (**Supplementary Figure S8B**). Analysis of loading  
188 values did not reveal SNPs or genomic regions with disproportionate influence on the observed population  
189 structure (**Supplementary Figure S9**). Genetic differentiation between populations is low overall ( $F_{st}$   
190 range = 0.002 - 0.008), and lowest between Amhara and Tigray regions ( $F_{st} = 0.002$ ) and highest between  
191 Gambella and Tigray regions ( $F_{st} = 0.008$ ), followed by between Amhara and Gambella ( $F_{st} = 0.003$ ).

### 192 **Genetic relatedness of *K13 622I* mutant and *pfhrp2/3*-deleted parasites**

193 IBD analysis revealed evidence of recent clonal transmission and spread of *K13 622I* parasites. Overall,  
194 10.6% of pairs are highly-related (IBD  $\geq 0.25$ , half siblings) (**Figure 5A**). We observe a tailed distribution  
195 of highly related parasite pairs, with 26.6% of pairwise comparisons sharing their genome with an IBD  
196 value of  $\geq 0.05$ . Comparing *K13 622I* mutant and wild-type parasites, we find significantly higher mean  
197 pairwise IBD sharing within *K13 622I* mutant populations (0.43 vs 0.08, respectively, Mann-Whitney  $p <$   
198 0.001) (**Figure 5B**). Network analysis of highly related parasites (pairwise IBD  $\geq 0.95$ ) shows that 622I  
199 mutant parasites tend to form related clusters and pairs separate from wild-type parasites (**Figure 5C**),  
200 consistent with clonal transmissions of 622I parasite populations in Ethiopia. The majority of clonal  
201 parasites carrying 622I mutation originated from one district (Tegede) (**Figure 5D**), likely illustrating an  
202 outbreak with rapid spread (**Table S1**).

203 *Pfhrp2/3*-deleted parasites also have higher relatedness than wild-type parasites, with significantly  
204 different pairwise IBD sharing (Kruskal-Wallis test  $p < 0.001$ ) when comparing *pfhrp2/3* double-, single-  
205 , and non-deleted parasites (**Figure 6A**). Pairwise IBD sharing is highest among *pfhrp2/3* double-deleted  
206 parasites, with 43.7% of comparisons having IBD  $\geq 0.25$  (half siblings), compared to only 4.3% of  
207 *pfhrp2/3* non-deleted parasites. Network analysis of highly related isolates (IBD  $\geq 0.95$ ) revealed  
208 clustering by deletion status (**Figure 6B**) with district-level clustering of *pfhrp2/3*-double deleted parasites  
209 evident in Kule, Atse-Tshimbila and West-Armachiho (**Figure 6C**), a finding consistent with clonal spread  
210 of *pfhrp2/3*-double deleted parasites at the local scale.

## 211 Discussion

212 Our genetic analysis confirms a widely prevalent WHO candidate artemisinin partial resistance *K13* 622I  
213 mutation across three regions of Ethiopia and suggests recent clonal spread. We observe low levels of  
214 polyclonality in this study consistent with previous study findings<sup>24</sup> and relatively low to moderate level  
215 malaria transmission intensity in these regions. Our findings suggest that independent transmission of  
216 highly related 622I or diagnostic-resistant *pfhrp2/3*-deleted parasites predominates with bursts of clonal  
217 spread. These findings suggest that Ethiopia's intensive test-and-treat strategies have exerted significant  
218 selective pressure on the *P. falciparum* population and are driving rapid expansion of artemisinin and  
219 diagnostic-resistant parasites. Though rare, identification of parasites carrying both 622I and *pfhrp2/3*  
220 deletion mutations raises concern that parasites with partial resistance to treatment and the ability to escape  
221 HRP2-based RDT detection are circulating in Ethiopia.

222 The presence of *K13* 622I across all sampled districts signals that parasites are under ACT pressure in  
223 Ethiopia and indicates that parasites are evolving to escape antimalarial treatment. The 622I mutation was  
224 reported previously in two small studies from one site in northern Ethiopia (Gondar), with associated delay  
225 in parasite clearance on day 3 of ACT<sup>26</sup> and increased prevalence over time, from 2.4% in 2014<sup>26</sup> to 9.5%  
226 in 2017-18<sup>27</sup>. While not yet peer reviewed, reports of 622I at high prevalence in Eritrea (16.7% in 2016)  
227 and association with 6.3% delayed clearance on day 3 of AL treatment raise further concern about this  
228 mutation<sup>33</sup>. The higher prevalence of the 622I mutation in northern Ethiopia (Amhara region) in our study  
229 suggests that it originated in northern Ethiopia or Eritrea, though our data are insufficient to determine its  
230 origins. The lower frequency of 622I vs. wild-type parasites in polyclonal infections provides evidence  
231 that it may decrease fitness within the human host, a consistent trait of artemisinin partial resistance



232 mutations due to loss of function within the *K13* propeller. Taken together, these findings suggest that 622I  
233 in Ethiopia represents a meaningful threat to elimination efforts across the Horn of Africa.

234 As transmission declines in Ethiopia and other settings nearing elimination, the majority of infected  
235 individuals are expected to carry single rather than multiple parasite strains. 82% of genotyped samples in  
236 our study are monogenomic, consistent with previous findings<sup>24</sup>. The associated increased rate of  
237 inbreeding in such settings<sup>34</sup> is known to favor the spread of drug-resistant strains<sup>35,36</sup>. Decreased parasite  
238 competition in low-transmission settings allows strains with resistance mutations that make them relatively  
239 less fit in the absence of drug pressure to expand. This is the case for artemisinin partial resistance. We  
240 previously showed that false-negative HRP2-based RDT results owing to *pfhrp2/3* deletions are common  
241 in Ethiopia and that *pfhrp2* deletion is under recent positive selection<sup>18</sup>. Using a larger MIP panel targeting  
242 SNPs across the genome for IBD analysis, we now found that these parasites are closely related and that  
243 bursts of clonal transmission appear to be occurring at the district or local scale. These findings support  
244 the idea that low transmission and associated parasite inbreeding are important for the expansion of  
245 *pfhrp2/3*-deleted populations. This also is consistent with the idea that outcrossing may disrupt co-  
246 transmission of *pfhrp2* and *pfhrp3* deletions given they are on separate chromosomes. The rare presence  
247 of parasites with both *K13* 622I and *pfhrp2/3* deletion mutations is not a reassuring finding. Their co-  
248 existence in a small number of parasites may simply be a consequence of their distinct origins and  
249 insufficient time for the expansion of 622I, *pfhrp2/3*-deleted parasite strains. While combined fitness costs  
250 may also play a role in the low prevalence of parasites with both mutations<sup>16,37</sup>, in the absence of inter-  
251 strain competition in low transmission settings, there are likely few barriers to the spread of 622I, *pfhrp2/3*-  
252 deleted parasites. Our expanded genetic analysis of drug-resistance mutations and parasite population  
253 structure confirms that close monitoring of emerging drug- and diagnostic-resistant strains is urgently  
254 needed to inform control strategies in the Horn of Africa and neighboring countries.

255 Different studies suggested that high efficacy of partner drugs (i.e. lumefantrine) impede the spread of  
256 ACT resistance in Africa<sup>16,37</sup>. However, we observe high prevalence of mutations associated with  
257 resistance to other antimalarial drugs our study, with nearly all genotyped samples carrying the ACT  
258 partner drug lumefantrine resistance haplotype (*pfmdr1* NFD)<sup>38,39</sup> and more than 80% carrying the *pfcr*  
259 N326S background mutation that augments artemisinin partial resistance. No parasites sampled in this  
260 study carried other common background mutations observed in SEA (*pfdd*-D193Y, *pfcr*-I356T, *pfarps*-

261 V127M and *pfmdr2*-T484I)<sup>31</sup>. Together, these findings support the need for close monitoring of  
262 lumefantrine efficacy and other partner drugs across Ethiopia.

263 IBD sharing was higher within the *K13* 622I mutant parasite population compared to wild-type parasites,  
264 suggesting that 622I mutation emerged or entered into northern Ethiopia in the recent past<sup>27</sup> and spread to  
265 other parts of the country. Highly related parasites are also closely clustered at the district level, a finding  
266 expected after clonal transmission. Moreover, our finding of parasites with high IBD and low overall COI  
267 in this study indicates low ongoing transmission across the three regions and that most recombination is  
268 between highly-related or clonal strains<sup>40,41</sup>. IBD analysis also showed high relatedness and clonal  
269 expansion of *pfhrp2/3* double-deleted parasites (most likely not detected by HRP2-based RDTs) at the  
270 local scale, with distinct populations of very closely related *pfhrp2/3*-deleted parasites observed in several  
271 districts. Clonal spread with local inbreeding could facilitate rapid spread of *pfhrp2/3*-deleted parasites  
272 that are expected to escape diagnosis by RDTs. Our data also reveals higher prevalence of 622I mutation  
273 among *pfhrp2/3* non-deleted compared to double-deleted parasites, a finding that might be seen when  
274 *pfhrp2/3* deletion leads to misdiagnosis, leaves patients untreated, and results in *pfhrp2/3*-deleted parasites  
275 exposed to less ACT pressure. Supporting this idea, we observed more frequent co-occurrence of *pfprt*-  
276 K76T mutation suggestive of empirical chloroquine treatment for presumed non-falciparum malaria.

277 Our study is not without limitations. First, travel histories from malaria cases and samples from  
278 neighboring countries are not included and thus tracking resistant strain importation is not addressed in  
279 detail. Second, the parent study was designed to evaluate RDT failure and could introduce selection bias,  
280 including under sampling of low-parasitemia and submicroscopic infections or oversampling of  
281 monogenomic infections. We therefore adjusted our *K13* 622I prevalence estimates to improve the  
282 generalizability of our findings. Third, the areas studied represent regions with relatively higher  
283 transmission (Amhara, Gambella and Tigray) and do not include other parts of the country, making it  
284 difficult to extrapolate our findings across the country. It may be that other regions have lower prevalences  
285 of drug and diagnostic resistance mutations, or that prevalences are even higher in lower transmission  
286 settings. Further study within Ethiopia and surrounding countries is warranted.

287 Overall, our study provides evidence that the ongoing selective pressures exerted on parasite populations  
288 in Ethiopia by HRP2-based RDT diagnosis<sup>42</sup> and ACT treatment<sup>43</sup> could facilitate co-occurrence of  
289 diagnostic and drug resistance, representing a double threat to malaria elimination. Ethiopia's recent

290 transition to alternative RDTs may reduce selective pressures favoring *pfhrp2/3*-deleted strains. However,  
291 we observe 622I mutation in multiple regions alongside *pfhrp2/3*-deleted parasites, and concerning  
292 examples of co-occurrence that could yield parasites resistant to both diagnosis and treatment. As Ethiopia  
293 and other countries in the Horn of Africa approach malaria elimination, diagnostic and drug resistance  
294 may be more likely to co-occur. These findings also illustrate the value of targeted parasite genomic  
295 analysis as part of large-scale malaria surveys and demonstrate the need for close monitoring of ACT  
296 efficacy that includes advanced molecular surveillance in Ethiopia.

## 297 **Materials and Methods**

### 298 **Study sites and sample genotyping**

299 A total of 920 samples from three regions (Amhara = 598, Gambella = 83 and Tigray = 239)  
300 (**Supplementary Figure S1**) previously assessed for *pfhrp2/3* deletions<sup>18</sup> were further genotyped using  
301 molecular inversion probes (MIPs). Sampling strategy, samples collection, DBS samples transportation,  
302 DNA extraction and initial molecular analysis were described in detail in our previous study<sup>18</sup>. The parent  
303 study was approved by the Ethiopian Public Health Institute (Addis Ababa, Ethiopia; protocol EPHI-IRB-  
304 033-2017) and the World Health Organization Research Ethics Review Committee (Geneva, Switzerland;  
305 protocol ERC.0003174 001). Parasite sequencing and analysis of de-identified samples was deemed  
306 nonhuman subjects research by the University of North Carolina at Chapel Hill (NC, USA; study 17-0155).

### 307 **MIP capture, sequencing and variant calling**

308 DNA originally isolated from DBS samples were captured and sequenced using two separate MIP panels:  
309 (1) a drug resistance panel (n = 814) designed to target mutations and genes associated with antimalarial  
310 resistance, and (2) a genome-wide panel (n = 1832) designed to target SNPs to evaluate parasite  
311 connectivity and relatedness (**Supplementary Data 1 and 2**)<sup>28,44</sup>. MIP capture and library preparation were  
312 performed as previously described<sup>17</sup>. Sequencing was conducted using an Illumina NextSeq 550  
313 instrument (150 bp paired-end reads) at Brown University (RI, USA).

314 The MIPtools (v0.19.12.13; <https://github.com/bailey-lab/MIPTools>) bioinformatic pipeline was used for  
315 processing of sequencing data and variant calling. Briefly, this pipeline employs MIPWrangler software  
316 to stitch paired reads, remove sequence errors, and predict MIP microhaplotypes leveraging the unique  
317 molecular identifiers (UMIs) in each arm. The haplotypes for each target were mapped to the *P. falciparum*

318 3D7 reference genome (PlasmoDB-42\_Pfalciparum3D7) using Burrows-Wheeler Aligner (BWA)<sup>45</sup> and  
319 variant calling was performed on these samples using freebayes<sup>46</sup>. Downstream analyses were performed  
320 on generated variant calling files (VCF) as well as translated tables based on 3D7 transcriptome for coding  
321 mutations. For genome-wide MIP panel, variants were quality filtered by removing those with less than  
322 three UMIs within a sample and less than 10 UMIs across the entire population. The drug resistance panel  
323 included known SNPs in *pfprt*, *pfdhfr*, *pfdhps*, *pfmdr1*, *K13* and other putative drug resistance genes and  
324 has been described elsewhere<sup>28</sup> (**Supplementary Data 2**). First prevalence was calculated as  $(p = m/n * 100$ ,  
325 where  $p$  = prevalence,  $m$  = number of infections with mutant alleles,  $n$  = number of successfully genotyped  
326 infections) (Table S3). Unweighted prevalence was calculated using the miplicorn R package version  
327 0.2.90 (<https://github.com/bailey-lab/miplicorn>) and vcfR R package version 1.13.0<sup>47</sup>. Mutant  
328 combinations were plotted and visualized using UpSet Package in R version 1.4.0<sup>48</sup>. Because dried blood  
329 spot sampling differed based on RDT results (participants with HRP2-/PfLDH+ results were purposefully  
330 oversampled for molecular characterization in the parent study), we adjusted our *K13* 622I prevalence  
331 estimates by weighting for the relative sampling proportions of RDT-concordant (HRP2+) and discordant  
332 (HRP2-/PfLDH+) samples. This was achieved by weighting RDT profile-specific prevalence estimates by  
333 the total number of *P. falciparum*-positive individuals presenting with that RDT profile in the parent study  
334 by district, region, and overall. Finally, 95% confidence intervals for these weighted prevalence estimates  
335 were estimated using bias corrected and accelerated (BCa) bootstrapping ( $n = 2000$  replications for district  
336 and region-level estimates,  $n = 3000$  replications for overall study estimate) using the R packages boot  
337 (version 1.3-28) and confintr (version 0.2.0). Mutant combinations were plotted and visualized using  
338 UpSet Package in R version 1.4.0<sup>48</sup>. For the genome-wide MIP panel, only biallelic variant SNPs were  
339 retained for analysis. Genome positions with more than 50% missing data (**Supplementary Figure S3A**),  
340 and samples missing 50% of sites (**Supplementary Figure S3B**) were removed leaving 609 samples and  
341 1395 SNPs from the genome-wide panel (**Supplementary Figure S4A**), which are distributed across 14  
342 *P. falciparum* chromosomes (**Supplementary Figure S4B**). The drug resistance panel includes SNPs  
343 across known *P. falciparum* drug resistance genes that have been described elsewhere<sup>28</sup>.

#### 344 **Complexity of infection analysis (COI)**

345 To estimate the COI, we used THE REAL McCOIL R package categorical method<sup>49</sup>. As DBS sampling  
346 in the parent study favored RDT discordant samples (HRP2-/pfLDH+) and could bias our COI estimates,  
347 we estimated overall and district level prevalence of monogenomic infections by weighting for the relative

348 sample proportions of RDT concordant and discordant samples in the parent survey. We also calculated  
349 within-host fixation index ( $F_{ws}$ ) using R package moimix 2.9<sup>50</sup> as another measure of within-host diversity  
350 of the parasites, which measures the probability that any random pair of infections carry different alleles  
351 at a specific locus. It was calculated for each infection as follows,  $F_{ws} = 1 - (H_w/H_s)$ , where  $H_w$  is the  
352 infection heterozygosity across all loci and  $H_s$  is the heterozygosity of the population from which the  
353 infection was sampled. As  $F_{ws}$  calculation based on the frequency of alleles per individual compared to  
354 that within the source population, it allows comparison between populations.  $F_{ws}$  range from 0 to 1, the  
355 sample was classified as having multiple infections (polyclonal) if  $F_{ws} < 0.95$  and monoclonal (single  
356 strain) infections if  $F_{ws} \geq 0.95$ . Samples with  $F_{ws} < 0.95$  were considered to come from mixed strain  
357 infections, indicating within-host diversity.

### 358 **Population structure and genetic differentiation**

359 To assess whether parasite populations within Ethiopia clustered based on their geographic origin, or  
360 *pfhrp2/3* deletion status, we first conducted principal component analysis (PCA) using SNPRelate R  
361 package version 1.30.1<sup>51</sup>. The eigenvalues generated from filtered VCF using snpgdsPCA function used  
362 as input file and the result was visualized using ggplot2 R package version 3.4.0. We calculated pairwise  
363 genetic differentiation ( $F_{ST}$ ) as a measure of genetic divergence between populations using PopGenome R  
364 package version 2.7.5<sup>52</sup>.

### 365 **Analysis of parasite relatedness using Identity-by-Descent (IBD)**

366 To measure relatedness between *P. falciparum* parasites and identify regions of the genome shared with  
367 recent common ancestry, the `inbreeding_mle` function of the MIPAnalyzer software version 1.0.0 was used  
368 on monogenomic samples to calculate IBD<sup>44</sup>. We determined IBD sharing variation at regional and local  
369 scale (district level) to assess spatial patterns of parasite connectivity and transmission dynamics at micro-  
370 local level comparing deleted and mutant parasites vs wild-type. Networks of highly-related parasites per  
371 *K13* 622I mutation status or *pfhrp2/3* deletion status were generated using the `igraph` R package version  
372 1.3.5<sup>53</sup>.

373 **Conflicts of Interest**

374 JBP reports research support from Gilead Sciences, non-financial support from Abbott Diagnostics, and  
375 consulting from Zymeron Corporation, all outside the scope of the current work. Other authors do not have  
376 a relevant conflict of interest to report.

377 **Funding**

378 This project was funded in part by the US NIH (R01AI132547 and K24AI134990 to J.J.J). The parent  
379 study was funded by the Global Fund to Fight AIDS, Tuberculosis, and Malaria through the Ministry of  
380 Health-Ethiopia (EPHI5405 to S.M.F.) and by the Bill and Melinda Gates Foundation through the World  
381 Health Organization (OPP1209843 to J.C., J.B.P.), with partial support from MSF Holland which  
382 supported fieldwork in the Gambella region. Under the grant conditions of the Bill and Melinda Gates  
383 Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author  
384 Accepted Manuscript version that might arise from this submission.

385 **Acknowledgments**

386 We thank the EPHI research teams for conducting the fieldwork during the parent study. We would also  
387 like to thank all of the participants and family members who contributed to this study.

388 **Data Availability**

389 All sequencing data available under Accession no. pending at the Sequence Read Archive (SRA)  
390 (pending), and the associated BioProject alias is pending.

391 **Author contributions**

392 AAF, JBP, JJJ and JAB conceived the study. SF led the parent study, with contributions from MH, BG,  
393 HM, BP, SH, JC, and JBP. AAF, CR, CH performed laboratory work. AAF led genetic data analysis and  
394 wrote the first draft of the manuscript. JBP, JJJ and JAB supported genetic data analysis and interpretations  
395 of results. All authors contributed to the writing of the manuscript and approved the final version before  
396 submission.

397



## 398 References

- 399 1. World Health Organization. *World malaria report 2022*. (World Health Organization, 2022).
- 400 2. Ringwald, P., Shallcross, L., Miller, J. M., Seiber, E. & World Health Organization. Roll Back  
401 Malaria Dept. *Susceptibility of Plasmodium falciparum to antimalarial drugs : report on global*  
402 *monitoring 1996-2004*. <https://apps.who.int/iris/handle/10665/43302> (2005).
- 403 3. Wellems, T. E. & Plowe, C. V. Chloroquine-resistant malaria. *The Journal of Infectious Diseases*  
404 vol. 184 770–776 Preprint at <https://doi.org/10.1086/322858> (2001).
- 405 4. Ross, L. S. & Fidock, D. A. Elucidating mechanisms of drug-resistant *Plasmodium falciparum*. *Cell*  
406 *Host Microbe* **26**, 35–47 (2019).
- 407 5. Takala-Harrison, S. & Laufer, M. K. Antimalarial drug resistance in Africa: key lessons for the  
408 future. *Ann. N. Y. Acad. Sci.* **1342**, 62–67 (2015).
- 409 6. Anderson, T. J. C. & Roper, C. The origins and spread of antimalarial drug resistance: lessons for  
410 policy makers. *Acta Trop.* **94**, 269–280 (2005).
- 411 7. Phyto, A. P. *et al.* Emergence of artemisinin-resistant malaria on the western border of Thailand: a  
412 longitudinal study. *Lancet* **379**, 1960–1966 (2012).
- 413 8. Imwong, M. *et al.* The spread of artemisinin-resistant *Plasmodium falciparum* in the Greater  
414 Mekong subregion: a molecular epidemiology observational study. *Lancet Infect. Dis.* **17**, 491–497  
415 (2017).
- 416 9. Roberts, L. Malaria wars. *Science* **352**, 398–402 (2016).
- 417 10. Dhorda, M., Amaratunga, C. & Dondorp, A. M. Artemisinin and multidrug-resistant *Plasmodium*  
418 *falciparum* - a threat for malaria control and elimination. *Curr. Opin. Infect. Dis.* **34**, 432–439  
419 (2021).
- 420 11. Marwa, K. *et al.* Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and  
421 dihydroartemisinin-piperaquine in the treatment of uncomplicated *Plasmodium falciparum* malaria  
422 in Sub-Saharan Africa: A systematic review and meta-analysis. *PLoS One* **17**, e0264339 (2022).
- 423 12. Tadele, G. *et al.* Persistence of residual submicroscopic *P. falciparum* parasitemia following  
424 treatment of artemether-lumefantrine in Ethio-Sudan Border, Western Ethiopia. *Antimicrob. Agents*  
425 *Chemother.* e0000222 (2022) doi:10.1128/aac.00002-22.
- 426 13. Ehrlich, H. Y., Bei, A. K., Weinberger, D. M., Warren, J. L. & Parikh, S. Mapping partner drug  
427 resistance to guide antimalarial combination therapy policies in sub-Saharan Africa. *Proc. Natl.*  
428 *Acad. Sci. U. S. A.* **118**, (2021).

- 429 14. Ndwiga, L. *et al.* A review of the frequencies of *Plasmodium falciparum* Kelch 13 artemisinin  
430 resistance mutations in Africa. *Int. J. Parasitol. Drugs Drug Resist.* **16**, 155–161 (2021).
- 431 15. Uwimana, A. *et al.* Emergence and clonal expansion of in vitro artemisinin-resistant *Plasmodium*  
432 *falciparum* kelch13 R561H mutant parasites in Rwanda. *Nat. Med.* **26**, 1602–1608 (2020).
- 433 16. Balikagala, B. *et al.* Evidence of artemisinin-resistant malaria in Africa. *N. Engl. J. Med.* **385**,  
434 1163–1171 (2021).
- 435 17. Moser, K. A. *et al.* Describing the current status of *Plasmodium falciparum* population structure and  
436 drug resistance within mainland Tanzania using molecular inversion probes. *Mol. Ecol.* **30**, 100–  
437 113 (2021).
- 438 18. Feleke, S. M. *et al.* *Plasmodium falciparum* is evolving to escape malaria rapid diagnostic tests in  
439 Ethiopia. *Nat Microbiol* **6**, 1289–1299 (2021).
- 440 19. Berhane, A. *et al.* Major threat to malaria control programs by *Plasmodium falciparum* lacking  
441 histidine-rich protein 2, Eritrea. *Emerg. Infect. Dis.* **24**, 462–470 (2018).
- 442 20. Prosser, C. *et al.* *Plasmodium falciparum* histidine-rich protein 2 and 3 gene deletions in strains  
443 from Nigeria, Sudan, and South Sudan. *Emerg. Infect. Dis.* **27**, 471–479 (2021).
- 444 21. Ayele, D. G., Zewotir, T. T. & Mwambi, H. G. Prevalence and risk factors of malaria in Ethiopia.  
445 *Malar. J.* **11**, 195 (2012).
- 446 22. Taffese, H. S. *et al.* Malaria epidemiology and interventions in Ethiopia from 2001 to 2016. *Infect*  
447 *Dis Poverty* **7**, 103 (2018).
- 448 23. Bugssa, G. & Tedla, K. Feasibility of malaria elimination in Ethiopia. *Ethiop. J. Health Sci.* **30**,  
449 607–614 (2020).
- 450 24. Lo, E. *et al.* Transmission dynamics of co-endemic *Plasmodium vivax* and *P. falciparum* in Ethiopia  
451 and prevalence of antimalarial resistant genotypes. *PLoS Negl. Trop. Dis.* **11**, e0005806 (2017).
- 452 25. Abamecha, A., Yilma, D., Adissu, W., Yewhalaw, D. & Abdissa, A. Efficacy and safety of  
453 artemether-lumefantrine for treatment of uncomplicated *Plasmodium falciparum* malaria in  
454 Ethiopia: a systematic review and meta-analysis. *Malar. J.* **20**, 213 (2021).
- 455 26. Bayih, A. G. *et al.* A unique *Plasmodium falciparum* K13 gene mutation in northwest Ethiopia. *Am.*  
456 *J. Trop. Med. Hyg.* **94**, 132–135 (2016).
- 457 27. Alemayehu, A. A. *et al.* Expansion of the *Plasmodium falciparum* Kelch 13 R622I mutation in  
458 northwest Ethiopia. (2021) doi:10.21203/rs.3.rs-171038/v1.
- 459 28. Aydemir, O. *et al.* Drug-resistance and population structure of *Plasmodium falciparum* across the

- 460 Democratic Republic of Congo using high-throughput molecular inversion probes. *J. Infect. Dis.*  
461 **218**, 946–955 (2018).
- 462 29. Verity, R. *et al.* The impact of antimalarial resistance on the genetic structure of *Plasmodium*  
463 *falciparum* in the DRC. *Nat. Commun.* **11**, 2107 (2020).
- 464 30. Malmberg, M. *et al.* *Plasmodium falciparum* drug resistance phenotype as assessed by patient  
465 antimalarial drug levels and its association with *pfmdr1* polymorphisms. *J. Infect. Dis.* **207**, 842–  
466 847 (2013).
- 467 31. Miotto, O. *et al.* Genetic architecture of artemisinin-resistant *Plasmodium falciparum*. *Nat. Genet.*  
468 **47**, 226–234 (2015).
- 469 32. Poti, K. E., Sullivan, D. J., Dondorp, A. M. & Woodrow, C. J. HRP2: Transforming malaria  
470 diagnosis, but with Caveats. *Trends Parasitol.* **36**, 112–126 (2020).
- 471 33. World Health Organization. Data on antimalarial drug efficacy and drug resistance (2010–2019).  
472 <http://www.jstor.org/stable/resrep30095.10> (2020).
- 473 34. Anderson, T. J. *et al.* Microsatellite markers reveal a spectrum of population structures in the  
474 malaria parasite *Plasmodium falciparum*. *Mol. Biol. Evol.* **17**, 1467–1482 (2000).
- 475 35. Cohen, J. M. *et al.* Malaria resurgence: a systematic review and assessment of its causes. *Malar. J.*  
476 **11**, 122 (2012).
- 477 36. Wasakul, V. *et al.* Malaria outbreak in Laos driven by a selective sweep for *Plasmodium falciparum*  
478 *kelch13* R539T mutants: a genetic epidemiology analysis. *Lancet Infect. Dis.* (2022)  
479 doi:10.1016/S1473-3099(22)00697-1.
- 480 37. Ashley, E. A. *et al.* Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N. Engl. J.*  
481 *Med.* **371**, 411–423 (2014).
- 482 38. Okell, L. C. *et al.* Emerging implications of policies on malaria treatment: genetic changes in the  
483 *Pfmdr-1* gene affecting susceptibility to artemether-lumefantrine and artesunate-amodiaquine in  
484 Africa. *BMJ Glob Health* **3**, e000999 (2018).
- 485 39. Veiga, M. I. *et al.* Globally prevalent *PfMDR1* mutations modulate *Plasmodium falciparum*  
486 susceptibility to artemisinin-based combination therapies. *Nat. Commun.* **7**, 115–53 (2016).
- 487 40. Nkhoma, S. C. *et al.* Close kinship within multiple-genotype malaria parasite infections. *Proc. Biol.*  
488 *Sci.* **279**, 2589–2598 (2012).
- 489 41. Camponovo, F., Buckee, C. O. & Taylor, A. R. Measurably recombining malaria parasites. *Trends*  
490 *Parasitol.* **39**, 17–25 (2023).

- 491 42. Rogier, E. *et al.* *Plasmodium falciparum* *pfhrp2* and *pfhrp3* gene deletions from persons with  
492 symptomatic malaria infection in Ethiopia, Kenya, Madagascar, and Rwanda. *Emerg. Infect. Dis.*  
493 **28**, 608–616 (2022).
- 494 43. Halsey, E. S. *et al.* Capacity development through the US President’s malaria initiative-supported  
495 antimalarial resistance monitoring in Africa network. *Emerg. Infect. Dis.* **23**, (2017).
- 496 44. Verity, R. *et al.* The impact of antimalarial resistance on the genetic structure of *Plasmodium*  
497 *falciparum* in the DRC. *Nat. Commun.* **11**, 2107 (2020).
- 498 45. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows–Wheeler transform.  
499 *Bioinformatics* **26**, 589–595 (2010).
- 500 46. Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing. *arXiv [q-*  
501 *bio.GN]* (2012).
- 502 47. Knaus, B. J. & Grünwald, N. J. vcfr: a package to manipulate and visualize variant call format data  
503 in R. *Mol. Ecol. Resour.* **17**, 44–53 (2017).
- 504 48. Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: an R package for the visualization of  
505 intersecting sets and their properties. *Bioinformatics* **33**, 2938–2940 (2017).
- 506 49. Chang, H.-H. *et al.* THE REAL McCOIL: A method for the concurrent estimation of the  
507 complexity of infection and SNP allele frequency for malaria parasites. *PLoS Comput. Biol.* **13**,  
508 e1005348 (2017).
- 509 50. Lee, S. & Bahlo, M. moimix: an R package for assessing clonality in high-throughput sequencing  
510 data. *moimix: an R package for assessing clonality in high*.
- 511 51. Zheng, X. *et al.* A high-performance computing toolset for relatedness and principal component  
512 analysis of SNP data. *Bioinformatics* **28**, 3326–3328 (2012).
- 513 52. Pfeifer, B., Wittelsbürger, U., Ramos-Onsins, S. E. & Lercher, M. J. PopGenome: an efficient Swiss  
514 army knife for population genomic analyses in R. *Mol. Biol. Evol.* **31**, 1929–1936 (2014).
- 515 53. Csárdi, G. & Nepusz, T. The igraph software package for complex network research. (2006).

516

517


518

519


520

521 **FIGURES**


A.



B.



C.




522

*K13* 622I status: Mutant, Wild-type, Previously reported

523 **Figure 1. Prevalence of *K13* and key drug-resistance mutations in Ethiopia.** A) Spatial distribution of  
 524 *K13* 622I mutation at the district (pie charts) and regional (bar plot) levels. Colors indicate mutation status,  
 525 and pie chart size is proportional to sample size per district. The black triangle indicates the location where  
 526 *K13* 622I mutation was reported previously. B) Prevalence of nonsynonymous mutations across the *K13*  
 527 gene, colored according to WHO ACT resistance marker category. *K13* gene annotation shows 1-350  
 528 amino-acid residues in the poorly conserved *Plasmodium*-specific region, and 350-726 residues in the beta  
 529 propeller domain where validated resistance mutations are located. C) Prevalence of mutations across four  
 530 key *P. falciparum* genes associated with commonly used antimalarial drugs (colors).

531



532

533 **Figure 2. Frequency of key drug resistance mutations.** The number of times each combination of  
 534 mutations was observed is displayed, including *K13 622I pfmdr1* N86 (wild), 184F (mutant), and D1246  
 535 (wild)); and *pfprt* genes. Results from monogenomic or the dominant haplotype in polygenomic infections  
 536 are shown. Only samples with complete genotypes across all loci are shown.


537

538

539

540







541

542 **Figure 3. *K13* 622I mutation among *pfhrp2/3*-deleted and *pfhrp2/3* non-deleted parasite populations.**  
543 **A)** Comparison of mean *K13* 622I mutation prevalence between *pfhrp2/3* double and *pfhrp2/3* non-deleted  
544 parasite populations by district across three regions in Ethiopia. **B)** Relationship between *pfhrp2/3* double-  
545 deleted parasite prevalence and *K13* 622I mutation prevalence by district. Prevalence estimates are  
546 weighted. Orange points represent districts where a parasite harboring both *pfhrp2-/3-* deletion and *K13*  
547 622I mutations are observed.

548






561

562 **Figure 5. Pairwise IBD sharing and relatedness networks suggest clonal transmission and expansion**  
 563 **of *K13 622I* parasites.** **A)** Pairwise IBD sharing across all three regions of Ethiopia. The plot shows the  
 564 probability that any two isolates are identical by descent, where the x-axis indicates IBD values ranging  
 565 from 0-1 and y-axis indicates the frequency (%) isolates sharing IBD. The inset highlights highly related  
 566 parasite pairs, with a heavy tail in the distribution and some highly related pairs of samples having IBD  $\geq$   
 567 0.95. **B)** Pairwise IBD sharing within parasites carrying *K13 622I* vs. wild-type. Boxes indicate the  
 568 interquartile range, the line indicates the median, the whiskers show the 95% confidence intervals, and  
 569 black dots show outlier values. *P* value determined using Mann-Whitney test is shown. **C)** Relatedness  
 570 network of highly related parasite pairs sharing IBD  $\geq$  0.95. Colors correspond to *K13 622I* mutant and  
 571 wild parasites. **D)** Relatedness network of only *K13 622I* parasite pairs sharing IBD  $\geq$  0.95 at the district  
 572 level/local scale. Colors correspond to districts across three regions in Ethiopia. In both panels C and D,  
 573 each node identifies a unique isolate, and an edge is drawn between two isolates if they share their genome  
 574 above IBD  $\geq$  0.95. Isolates that do not share IBD  $\geq$  0.95 their genome with any other isolates are not  
 575 shown.

576

577

578



579

580 **Figure 6. Pairwise IBD sharing and relatedness networks suggest independent emergence and clonal**  
581 **spread of *pfhrp2/3*-deleted parasites.** A) Pairwise IBD sharing by *pfhrp2/3* deletion status. Boxes  
582 indicate the interquartile range, the line indicates the median, the whiskers show the 95% confidence  
583 intervals, and black dots show outlier values. *P* values were determined using the Kruskal-Wallis test. B)  
584 Relatedness network of highly related parasite pairs sharing IBD  $\geq 0.95$ . Each node identifies a unique  
585 isolate, and an edge is drawn between two isolates if they share their genome with IBD  $\geq 0.95$ . Isolates  
586 that do not share their genome IBD  $\geq 0.95$  with any other isolates are not shown. Color codes correspond  
587 to *pfhrp2/3* deletion status. C) Relatedness network of *pfhrp2/3* double-deleted parasite pairs with IBD  $\geq$   
588 0.95 at district level/local scale. Colors correspond to districts across three regions of Ethiopia.

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603 **SUPPLEMENTARY MATERIAL**

604 **Supplementary Tables**

605 *Supplementary tables are compiled into a single file for ease of viewing.*

606 **Table S1.** Prevalence of monogenomic infections per district weighted by RDT discordant prevalence.

607 **Table S2.** Weighted prevalence of key drug resistance mutations per district. Weighting calculated by  
608 RDT profile (see Methods).

609 **Table S3.** District level prevalence (unweighted) of all nonsynonymous mutations across different drug  
610 resistance genes. The prevalence of antimalarial resistance mutations detected by the MIPs is shown for  
611 each geographic location. Mutations above 1% prevalence in any of the districts shown. AA = mino Acid;  
612 n = number of samples genotyped; m = number of samples carry mutant allele.

613

614 **Supplementary Data**

615 *Supplementary tables are compiled into a single file for ease of viewing.*

616 **Data 1.** List of loci included in genome wide MIP panel.

617 **Data 2.** List of loci included in drug resistance MIP panel.

618 **Data 3.** Metadata for 609 successfully sequenced samples using the genome wide MIP panel. This data  
619 was used for COI estimation and population genetic analysis.


620 **Data 4.** Metadata and genotype file for all successfully sequenced samples (varies per marker) using the  
621 drug resistance MIP panel. Only successfully sequenced samples were used for drug resistance marker  
622 prevalence estimates. 0 = Reference Call, 1 = Alternative heterozygous call, 2= Alternative homozygous  
623 call, -1 = Missing call.

624

625


626

627 **Supplementary Figures**



628


629 **Figure S1.** Description of sequenced samples. Spatial distribution of sequenced samples at district level (color  
630 dots in map) and regional level (color bar plot). Colors indicate regions.



631


632 **Figure S2. PCR parasitemia distribution and association between sequencing coverage and parasitaemia.**  
633 **A)** Density plot showing parasitemia distribution with median parasitemia = 1411 parasite/ul. **B)** Association  
634 between sequencing coverage and parasitaemia. The MIP sequencing success is parasitaemia dependent as shown  
635 in the heatmap color.





636

637 **Figure S3. Sample (A) and SNP (B) missingness.** A) Samples with >50% low-coverage loci were dropped as  
 638 shown broken read line. B) Variant sites were then assessed by the same means in terms of the proportion of low-  
 639 coverage samples, and sites with >50% low-coverage samples were dropped. Broken read line shows 50%  
 640 threshold criteria we used to remove samples and loci from downstream analyses.




641

642 **Figure S4. Successfully sequenced samples across three regions in Ethiopia and retained genome wide loci.**  
 643 A) Association between sequencing coverage and parasitaemia. The MIP sequencing success is parasitaemia  
 644 dependent as shown in the heatmap color. B) Distribution of retained SNPs across *Plasmodium falciparum*  
 645 chromosomes. The plot shows distribution of 1395 retained high quality biallelic SNPs across the 14 *P.*  
 646 *falciparum* chromosomes within 0.025 Mb window size. Color coded from light gray for masked regions with no  
 647 SNPs to red for regions containing high number SNPs per chromosome.

648

649




650

651 **Figure S5. Complexity of infections.** **A)** Distribution Number of clones per sample across genotyped samples  
652 showing most of isolates carrying one clone (COI=1). **B)** Cumulative within-infection FWS fixation showing  
653 majority of isolates classified as monogenomic ( $F_{WS} > 0.95$ ). Number of clones per sample. **C)** Spatial  
654 heterogeneity of mean complexity of infections per district across three regions in Ethiopia. Vertical lines show 95%  
655 confidence intervals.

656


657



658

659 **Figure S6. Prevalence of *Pfdhfr* and *Pfdhps* mutations across Ethiopia.** **A)** UpSet plots showing the number of  
 660 times each combination of mutations was seen for *Pfdhfr* and *Pfdhps*. **B)** Spatial distribution of *Pfdhps* A581G  
 661 mutation at district level. Colors indicate mutation status and size of pie chart is proportional to sample size per  
 662 district.

663




664

665 **Figure S7. Prevalence of *pfcr1* mutations.** The UpSet plot shows the number of times each combination of  
 666 mutation was observed within *pfcr1* (A), and prevalence of these mutations by *pfhrp2/3* status (B).

667


668



669

670 **Figure S8. Population structure of *P. falciparum* in Ethiopia.** A) Principal component analysis *P. falciparum*  
671 populations per region. Colors indicate sample origin and shape indicates *K13* 622I mutation status (circle indicates  
672 wild and diamond indicates mutant). Percentage of variance explained by each principal component presented (%).  
673 B) Percent of overall variance explained by the first 10 principal components during PCA.

674



675

676 **Figure S9. PCA loading values.** PC1 (A) and PC2 (B) are shown by SNP. Cutoffs show SNPs that highly  
677 contribute to positive or negative distribution of samples in the PC plots.

678